- NEWS
Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common illnesses.
A CRISPR–Cas9 gene-editing therapy has halved people’s cholesterol levels in a small clinical trial — raising hopes that, with further study, gene editing could one day be harnessed to provide a one-stop treatment for a common cause of heart disease.
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 647, 832-833 (2025)
doi: https://doi.org/10.1038/d41586-025-03711-3
References
Laffin, L. J. et al. New Engl. J. Med. https://doi.org/10.1056/NEJMoa2511778 (2025).
Lazzarotto, C. R. et al. Preprint at bioRxiv https://doi.org/10.1101/2025.02.10.637517 (2025).
Related Articles
-
World first: ultra-powerful CRISPR treatment trialled in a person
-
Hope for diabetes: CRISPR-edited cells pump out insulin in a person – and evade immune detection
-
CRISPR genome-editing grows up: advanced therapies head for the clinic
-
The hunt for the next CRISPR: how warring microbes are inspiring new technology
